Abstract 1944P
Background
T-cell based therapies are currently explored in clinical trials (NCT04044768, NCT01343043) in patients with synovial sarcoma (SySa). These therapies are targeting cancer testis antigens like Melanoma-Associated Antigen 4 (MAGE-A4) or New York Esophageal Squamous Cell Carcinoma-1 (NY-ESO-1). We explored the molecular epidemiology of these targets using a tissue micro-array (TMA) from clinical SySa samples.
Methods
We created a TMA consisting of 323 cores from 108 clinical samples (≥2 cores/sample) from archival, paraffin-embedded material originating from 91 individual donors. A sarcoma reference pathologist verified the diagnosis of SySa in the donor sample. Most samples (62%) were collected from the primary tumour, 22% and 16% originated from a metastasis or local recurrence. Slides were stained with MAGE-A4 antibody (#82491, dilution 1:100, Cell Signaling) and NY-ESO-1 antibody (clone E978, dilution 1:200, Sigma), during an overnight incubation. Normal human testis tissue was used as a positive control. Expression of each core was scored as an H-score, defined as: (% stained cells at 0 intensity) × 0 + (% stained cells at 1+ intensity) × 1 + (% stained cells at 2+ intensity) × 2 + (% stained cells at 3+ intensity) × 3. The average of the H-scores from the cores corresponding to the same tumour sample was used for subsequent analyses. Expression of the target was defined as an average H-score ≥ 1 and high expression was defined as an average H-score > 100. Kruskal-Wallis test was used for the statistical analyses.
Results
Expression of NY-ESO-1 and MAGE-A4 was found in 50.9% (55/108) and 68.5% (74/108) of TMA samples. High expression was noticed in 20/108 samples (18.5%) for NY-ESO-1 and in 25/108 samples (23.1%) for MAGE-A4. In 77.8% of the samples there is at least one of these cancer testis antigens expressed. There was no correlation between the expression level and disease status at the sampling moment, nor with clinical outcome of the patient. Additionally, there was no correlation between the expression level and the size of the original tumour.
Conclusions
MAGE-A4 and NY-ESO-1 are expressed in a clinically relevant proportion of SySa cases represented in our TMA, this supports the utility of these antigens as targets for novel cell-based therapies in this disease.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1840P - RNASEH2B loss and PARP inhibition (parpi) in metastatic castration resistant prostate cancer (mCRPC)
Presenter: Juliet Carmichael
Session: Poster session 15
1841TiP - Darolutamide plus androgen-deprivation therapy (ADT) in patients with high-risk biochemical recurrence (BCR) of prostate cancer: A phase III, randomized, double-blind, placebo-controlled study (ARASTEP)
Presenter: Alicia Morgans
Session: Poster session 15
1842TiP - Phase II randomized trial of two dose levels of vobramitamab duocarmazine in participants with metastatic castration resistant prostate cancer (mCRPC; TAMARACK)
Presenter: Johann de Bono
Session: Poster session 15
1922P - Immunosarc II master trial: phase II of sunitinib and nivolumab in vascular sarcomas cohort - A GEIS, ISG and UCL study
Presenter: Nadia Hindi Muñiz
Session: Poster session 15
1923P - Combined analysis of phase III ANNOUNCE study and phase II study exploring olaratumab in advanced soft tissue sarcoma
Presenter: Yoichi Naito
Session: Poster session 15
1924P - Targeting microenvironment and cellular immunity in sarcomas with trabectedin combined with metronomic cyclophosphamide: The TARMIC study
Presenter: Cheng-Ming Sun
Session: Poster session 15
1925P - Results of SOC-2082 phase II study using metronomic gemcitabine, doxorubicin, and docetaxel plus nivolumab as second/third-line therapy for advanced leiomyosarcoma
Presenter: Neal Chawla
Session: Poster session 15
1926P - Trabectedin plus radiotherapy on symptomatic advanced sarcoma patients: Results from the SYNERGIAS study - A Spanish group for research in sarcoma (GEIS) phase II study
Presenter: Javier Martin-Broto
Session: Poster session 15
1927P - Epithelioid hemangio-endothelioma (EHE) in NETSARC: The nationwide series of 267 patients over 12 years
Presenter: Axel Le Cesne
Session: Poster session 15
1928P - Differential presentation and outcome of sclerosing epithelioid fibrosarcoma (SEF) vs low grade fibromyxoid sarcoma (LGFMS): The nationwide series of 330 patients in NETSARC since 2010
Presenter: Jean-Yves Blay
Session: Poster session 15